Immunohistochemical Detection of Breast Cancer Stem Cells in Hormone Receptor-Positive Breast Cancer and Their Role in Response to Endocrine Therapy and Clinical Outcome

Oncology ◽  
2012 ◽  
Vol 82 (3) ◽  
pp. 168-174 ◽  
Author(s):  
Kenji Hashimoto ◽  
Chikako Shimizu ◽  
Hitoshi Tsuda ◽  
Shigehira Saji ◽  
Akihiko Osaki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Clinical Outcome ◽  
Endocrine Therapy ◽  
Hormone Receptor ◽  
Breast Cancer Stem Cells ◽  
Immunohistochemical Detection ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

scholarly journals Breast Cancer Stem Cells and Their Role in Resistance to Endocrine Therapy

2011 ◽  
Vol 2 (2) ◽  
pp. 91-103 ◽  
Author(s):  
Ciara S. O’Brien ◽  
Gillian Farnie ◽  
Sacha J. Howell ◽  
Robert B. Clarke
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Endocrine Therapy ◽  
Breast Cancer Stem Cells

scholarly journals Doxycycline targets aldehyde dehydrogenase‑positive breast cancer stem cells

2018 ◽  
Author(s):  
Chang‑Ching Lin ◽  
Miao‑Chia Lo ◽  
Rebecca Moody ◽  
Nicholas Stevers ◽  
Samantha Tinsley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Aldehyde Dehydrogenase ◽  
Breast Cancer Stem Cells ◽  
Positive Breast Cancer

scholarly journals Endocrine Therapy in Premenopausal Hormone Receptor–Positive Breast Cancer

2016 ◽  
Vol 12 (11) ◽  
pp. 1148-1156 ◽  
Author(s):  
Amye J. Tevaarwerk ◽  
Kari B. Wisinski ◽  
Ruth M. O’Regan
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Systemic Therapy ◽  
Hormone Receptor ◽  
Randomized Trials ◽  
Early Stage ◽  
Premenopausal Women ◽  
Breast Cancers ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

Systemic therapy for premenopausal women with hormone receptor–positive breast cancer has evolved in the last 5 years, but critical questions remain. Recent randomized trials have demonstrated a benefit for the addition of ovarian suppression to endocrine therapy in patients with breast cancers considered to be at high risk for recurrence, whereas those with lower-risk cancers seem to have a favorable outcome with tamoxifen alone. Two large randomized trials have demonstrated a benefit for extending adjuvant tamoxifen beyond 5 years. Currently the choice of systemic therapy is selected empirically but molecular profiling may, in the near future, provide a more conclusive means of selecting an endocrine therapeutic approach for premenopausal patients. Given that a significant subset of hormone receptor–positive cancers are intrinsically resistant to endocrine agents, as well as the finding that inhibiting cyclin-dependent kinases 4 and 6 and mammalian target of rapamycin appears to potentially reverse this resistance in patients with metastatic disease, evaluation of these agents in the early-stage setting is ongoing.

Sign in / Sign up

Export Citation Format

Share Document